Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis

Abstract Sorafenib is the main treatment for advanced hepatocellular carcinoma (HCC), but drug resistance limits its effectiveness. Evidence increasingly indicates that, in addition to targeting tyrosine kinases, sorafenib also induces ferroptosis. However, current studies have not fully clarified t...

Full description

Saved in:
Bibliographic Details
Main Authors: Junren Lu, Daming Cai, Long Qian, Yurong Wang, Shichao Ai, Peng Song, Feng Sun, Yiwen Sun, Mengjie Liang, Hang Jiang, Xingzhou Wang, Meng Wang, Xiaofeng Lu, Wenxian Guan, Xiaofei Shen
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01004-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-025-01004-6

Similar Items